Dr. Krzysztof Kiryluk is an Associate Professor of Medicine (with tenure) at Columbia University. He received his medical degree at the Columbia College of Physicians & Surgeons, completed his residency in Internal Medicine at the Massachusetts General Hospital, Harvard University, and Nephrology fellowship training at the NewYork-Presbyterian Hospital, Columbia University. Dr. Kiryluk specializes in the treatment of chronic kidney disease, glomerulonephritis, and inherited kidney disorders.

Dr. Kiryluk is a physician-scientist, and he serves as the Director of Clinical Research in the Division of Nephrology at Columbia University. His research aims to define genetic factors contributing to the risk of kidney disease. Dr. Kiryluk leads several large collaborative national and international genetic studies of glomerular disorders, such as IgA nephropathy, IgA vasculitis, and membranous nephropathy. Some of Dr. Kiryluk's interests fall at the interface of research and clinical care. For example, he is leading precision medicine studies involving integrated genomic risk assessment with return of genetic results to patients and clinicians. He is also working on the development of new informatics methods to harness the power of "big data" (clinical and molecular) to enhance genetic discovery and improve clinical care of kidney patients.

Dr. Kiryluk has authored multiple publications and is a recipient of several prestigious awards, including the Donald W. Seldin Young Investigator Award from the American Society of Nephrology. He is an active member of the American Society of Clinical Investigation, American Society of Human Genetics, American Society of Nephrology, and International Society of Nephrology. He also serves as an associate editor of Kidney International. His research has been supported by federal grants from the National Institute of Diabetes and Digestive and Kidney Disease, National Human Genome Research Institute, National Center for Advancing Translational Sciences, National Library of Medicine, as well as private foundations.